Medications for Neurofibromatosis Type 1 (NF1)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Neurofibromatosis Type 1 (NF1).
Found 2 Approved Drugs for Neurofibromatosis Type 1 (NF1)
Koselugo
Generic Name
Selumetinib
Koselugo
Generic Name
Selumetinib
Form: Capsule
Method of administration: Oral
FDA approval date: April 16, 2020
Classification: Kinase Inhibitor
KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). ( 1 )
Gomekli
Generic Name
Mirdametinib
Gomekli
Generic Name
Mirdametinib
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: February 11, 2025
GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. GOMEKLI is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. ( 1 )
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances